CRO Theorem Clinical Research has struck a deal with a healthcare analytics firm, giving it access to economics and outcomes research technology the company said can help drug developers make the right decisions throughout the R&D process.
Teaming up with Decision Driver Analytics, Theorem can now draw on health economists, epidemiologists, biostatisticians, medical writers and reimbursement experts to model outcomes and predict returns on investment in each stage of drug and medical device development, from discovery to marketing, the company said. With that information, clients can better choose how or whether to move forward with their programs, potentially cutting costs and avoiding developmental pratfalls, Theorem CEO John Potthoff said.
"The clinical studies that may prove a scientific point are really only one aspect of a successful drug or medical device development program," Potthoff said in a statement. "Decision Driver Analytics' product life cycle value analysis and exceptional economic insight help clients make high-value decisions with confidence throughout the entire development process."
Over the past few years, the mid-sized Theorem has doubled down on medical devices and diagnostics to stand out in the competitive CRO world, teaming up with Emergo last year to add med tech to its already-established services in biologics and small-molecule projects. And the CRO is targeting early-stage growth, as well, signing a preclinical deal with Charles River Labs ($CRL) in September to bolster its bioanalysis, immunogenicity and immunology testing.
- read the statement